US Protein and Peptide Therapeutics Market Insight
US protein and peptide therapeutics market size is growing at a 7.80% CAGR, driven by increasing prevalence of chronic diseases, rising demand for targeted biologic therapies
US Protein and Peptide Therapeutics Market Insights Forecasts to 2035
- The US Protein and Peptide Therapeutics Market Size Was Estimated at USD 165.0 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.80% from 2025 to 2035
- The US Protein and Peptide Therapeutics Market Size is Expected to Reach USD 350.0 Billion by 2035
Notable Insights for US Protein and Peptide Therapeutics Market
- By product type, monoclonal antibodies dominated the market, generating approximately USD 75.0 Billion in revenue in 2024 due to their widespread use in oncology and autoimmune disease treatment.
- By application, oncology is expected to witness the fastest growth, supported by increasing cancer prevalence and advancements in targeted therapies.
- Approximately 72% of demand is driven by oncology, metabolic disorders, and immunological diseases, while nearly 60% growth is supported by innovations in biologics, recombinant proteins, and peptide engineering. Additionally, increasing investment in biopharmaceutical R&D is supporting market expansion.
- Growing adoption of biologic drugs, increasing focus on personalized medicine, and advancements in protein engineering technologies are driving market growth.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Protein and Peptide Therapeutics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in US Protein and Peptide Therapeutics Market
- Amgen Inc.
- Pfizer Inc.
- Johnson & Johnson
- Eli Lilly and Company
- Merck & Co., Inc.
- Novo Nordisk A/S
- Sanofi S.A.
- AbbVie Inc.
- Others
Recent Developments:
- In November 2025, Amgen Inc. expanded its biologics portfolio with advanced protein-based therapeutics.
- In July 2024, Eli Lilly and Company introduced innovative peptide therapies targeting metabolic disorders.
Market Segmentation:
US Protein and Peptide Therapeutics Market, By Product Type
- Monoclonal Antibodies
- Insulin
- Fusion Proteins
- Peptides
US Protein and Peptide Therapeutics Market, By Application
- Oncology
- Metabolic Disorders
- Immunological Diseases
- Cardiovascular Diseases
- Others
US Protein and Peptide Therapeutics Market, By End User
- Hospitals
- Specialty Clinics
- Research Institutes
Expert Views:
The US Protein and Peptide Therapeutics Market is expected to witness strong growth, driven by increasing demand for biologic and targeted therapies. Experts highlight that advancements in biotechnology, expansion of personalized medicine, and rising investments in drug development will significantly shape future market trends.